Printed from Voxsanity (voxsanity.com.au) — NCT07181811 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Multiple Sclerosis
Multiple Sclerosis Trial, Not Yet Recruiting
NCT07181811
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 to 75, both men and women.
- People with a confirmed diagnosis of Multiple Sclerosis (MS), including relapsing or progressive forms.
- People whose level of physical disability falls within a specific measured range (a score between 0 and 7.5 on a standard MS disability scale — confirm with trial site if unsure what this means for a specific case).
- People who have been continuously taking the MS medication ocrelizumab for at least one year.
- Women who could become pregnant must agree to avoid pregnancy during the study and for 6 months after their last ocrelizumab dose, using abstinence or an accepted form of contraception, and must have a negative pregnancy test before joining.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose MS diagnosis has not been confirmed using a specific set of diagnostic guidelines (the McDonald 2017 Criteria).
- People who have not been taking ocrelizumab for at least 6 months before the study begins.
- People who are currently taking other MS disease-modifying medications alongside ocrelizumab.
- People who have had an MS relapse or have used corticosteroid medications within the past 30 months before joining.
- People with a history of major psychiatric conditions — such as severe depression, schizophrenia, or bipolar disorder — that would interfere with assessments.
- People with significant memory or thinking difficulties caused by conditions unrelated to MS, such as brain injury, dementia, or other brain diseases.
- People with other major neurological disorders, such as Parkinson's disease, epilepsy, or stroke.
- People with a history of alcohol or substance misuse within the past year.
- People with serious uncontrolled health conditions, such as severe heart disease, diabetes with complications, or kidney or liver failure.
- People with uncorrected vision or hearing problems that would interfere with cognitive testing.
- People who are unable to give informed consent due to cognitive difficulties or legal reasons.
- People who are pregnant, breastfeeding, or planning to become pregnant during the study.
- People who are currently taking part in another interventional clinical trial that affects thinking ability or fatigue outcomes.
- People with known recurring or chronic infections such as HIV, syphilis, or tuberculosis.
- People with a history or presence of infections that can affect the spinal cord, such as syphilis, Lyme disease, or a virus called HTLV-1.
- People with an active bacterial, viral, fungal, or mycobacterial infection that has recently required hospitalisation or intravenous (IV) antibiotics.
- People with a history of cancer, except for certain treated skin cancers or resolved cervical cancer that has been successfully treated (confirm with trial site for details).
- People with a history of, or currently active, primary or secondary immune system deficiency.
- People who have had severe allergic or anaphylactic reactions to monoclonal antibody medications.
- People with systemic autoimmune conditions that cause progressive neurological disease, such as lupus or Sjögren's syndrome.
- People who require ongoing use of corticosteroids or immune-suppressing medications for another condition.
- People with significant uncontrolled disease affecting the heart, lungs, kidneys, liver, hormone-producing glands, or digestive system.
- People with a history of certain other neurological disorders, including conditions such as a brain infection called PML, tumours of the brain or spinal cord, certain hereditary or genetic neurological conditions, or a condition called neuromyelitis optica spectrum disorder (confirm with trial site for the full list).
- People who have used systemic corticosteroid therapy within 4 weeks before the study baseline visit.
- People who have previously been treated for MS with cyclophosphamide, mitoxantrone, or bone marrow transplant.
- People who have received any vaccine — live, attenuated, or inactivated — within 6 weeks before joining the trial.
- People with certain abnormal blood test results, including positive hepatitis B markers, elevated liver enzymes, low blood cell counts, or low levels of certain antibodies (IgG or IgM).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Phone: 313-576-0298
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Anza Memon
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
1 June 2028
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Change in global cognitive performance; Change in fatigue impact (Modified Fatigue Impact Scale, MFIS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.